Bolt Biotherapeutics is developing its novel BoltbodyTM platform, a cancer immunotherapy that consists of Immune-Stimulating Antibody Conjugates (ISAC).
Bolt Biotherapeutics is a biotechnology company in California that focuses on developing a platform for cancer immunotherapy. Founded 2015 in Redwood City, California, United StatesUnited States by CP Liu and Edgar Engleman, Bolt Biotherapeutics is a developer of bio-therapeutics designed to cure cancer models. The company's bio-therapeutic products enable physicians to treat various forms of cancer. Bolt Biotherapeutics is a platform consisting of systemically delivered Immune-Stimulating Antibody Conjugates (ISAC) called the BoltbodyTM ISACS. These antibody conjugates reinvigorate the immune system and build an understanding of how dendritic and other myeloid cells generate effective anti-tumor immunity. These are immuno-oncology therapies that generate systemic immunological memory.